Scienion AG

Scienion AG specializes in precision dispensing technologies for the life sciences sector, providing innovative solutions for diagnostics and therapeutic development through advanced dispensing systems. Scienion AG is focused on precision dispensing technologies that serve the life sciences and diagnostics industries. Founded in 2001 in Dortmund, Germany, the company was acquired by Cellink AB in August 2020 for EUR 80 million in cash and stock. The company has completed a total of 3 deals since its inception.

The CEO, Frauke Hein, has been instrumental in guiding the firm through its growth phases. Scienion offers advanced solutions, including the sciFLEXARRAYER series for ultra-low volume dispensing and the cellenONE technology for single-cell isolation. These innovations cater to multiplexed assays, drug delivery systems, and cellular analysis, serving customers in healthcare, pharmaceuticals, biotech, and research institutions across North America, Europe, and Asia. In 2019, Scienion reported revenue of EUR 21,150,080 and an EBITDA of EUR 5,518,336.

The company's revenue model is based on B2B sales of dispensing systems, consumables, and associated services, creating steady income through long-term contracts and partnerships. Following the acquisition by Cellink AB, Scienion plans to capitalize on new opportunities in the life sciences sector. The recent funding from the EUR 80 million Trade Sale will be utilized to enhance product development and expand market reach, particularly targeting North America and Europe. Scienion aims to introduce innovative products designed for upcoming applications in diagnostics and therapeutic development within the next two years.